HCV慢性感染者抗F蛋白抗体影响因素研究

目的探讨丙型肝炎病毒（hepatitisCvirus，HCV）慢性感染者抗F蛋白抗体阳性率的影响因素。方法收集215例抗HCV抗体阳性患者的血清标本，用间接酶联免疫吸附法（enzyme—linkedimmunosorbentassay，ELISA）检测血清抗F蛋白抗体，并进行HCVRNA检测和基因分型。结果抗F蛋白抗体阳性率为66．0％（142／215）；单因素分析结果显示，年龄20～岁和51～岁间抗F抗体阳性率差异有统计学意义（P〈0．001）、是否合并肝硬化的F抗体阳性率差异有统计学意义（P=0．020），而性别、HCV1b和2型、HCVRNA阳性和阴性抗F抗体阳性率间差异均无统计学意义（均有P〉0．05）；将年龄和肝硬化纳入Logistic回归模型得出，年龄为51～岁以及合并肝硬化会增加血清抗F蛋白抗体阳性的可能性，OR（95％CI）值分别为3．45（1．56～7．62）和1．35（1．05—1．73）。结论年龄增长、合并肝硬化会增加血清抗F蛋白抗体阳性的可能性，性别、HCV分型及HCVRNA则不会影响。

Study of influencing factors of serum anti-F antibody in HCV chronic infected patients

Objective To investigate the distribution and influencing factors of serum anti-F in patients with chro- nic hepatitis C virus （HCV） infection. Methods Serum samples of 215 HCV chronic infected patients were recruited. In- direct enzyme-linked immuno sorbent assay （ELISA） were employed to detect serum anti-F protein antibody. HCV RNA and genotyping were detected respectively. Results There were significant correlations among anti-F antibody, age and patients with cirrhosis, but not sex, HCV RNA or types of HCV RNA. Logistic regression analysis showed that the positive rate of anti-F was higher in patients over 50 years old（ OR = 3.45,95% CI： 1.56-7.62）, and in patients with cirrhosis （ OR = 1.35,95% CI： 1.05-1.73 ）. Conclusions The results indicate that age and cirrhosis play roles in the anti-F anti- body in patients with chronic HCV infection.